A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
A legfontosabb adatok
- Ki végzi
- Janssen Research & Development, LLC
- Hol
- Adelaide (Ausztrália)A helyszín megnézéseMég 2 másik országban, 9 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 170 fő, tervezett
- Kezdés
- 2026. ápr. 9.
- Várható befejezés
- 2030. ápr. 15.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- JNJ-101684362 (HLD-0117)
- A regiszteradat frissítve
- 2026. november 3.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Csak nők
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- Female (assigned at birth), greater than or equal to (>=) 18 years old, and able to provide informed consent
- Histologically confirmed metastatic or locally advanced breast cancer
- Postmenopausal status defined by surgical or natural menopause, or ovarian suppression with a GnRH agonist
- Prior therapy including; Must have received at least one endocrine therapy in the metastatic setting; Must have received at least one cyclin-dependent kinase (CDK) 4/6i, either in the adjuvant and/or metastatic setting; For Part 1 and Part 2 Cohorts 2A, 2B, 2C, and 2D: Participants may have received up to two prior distinct cytotoxic regimens (for example, taxanes, antibody-drug conjugates (ADCs), etc.) in the metastatic setting, unless discussed and approved by the medical monitor; For Part 2 Cohort 2E: Participants must have received more than two prior distinct cytotoxic regimens (for example, taxanes, ADCs, etc.) in the metastatic setting
- Radiologic disease progression on the most recent therapy
- Patients must have disease evaluable per response evaluation criteria in solid tumors (RECIST) v1.1; For Part 1 and Part 2B, 2C, and 2E: Participants may have either evaluable or measurable disease per RECIST v1.1; For Part 2 Cohort 2A: Participants should have measurable soft tissue disease per RECIST v1.1; For Part 2 Cohort 2D: Participants should have evaluable but not measurable disease
- Willingness to provide baseline and on-treatment tumor biopsies, unless not feasible or medically appropriate
- For Part 1 and Part 2 (all cohorts):; Participants must have documented >=10% ER staining and human epidermal growth factor receptor 2 (HER2) negative (per american society of clinical oncology [ASCO] college of american pathologists [CAP] guidelines) on the most recent tumor biopsy sample obtained; For Part 2 Cohort 2B: Participants must have recent estrogen receptor 1 gene (ESR1) wild type from tumor or circulating tumor deoxy ribonucleic acid (ctDNA) testing performed after the most recent endocrine therapy prior to enrollment; For Part 2 Cohort 2C: Participants must have ESR1 mutation detected from tumor or ctDNA testing performed prior to enrollment
- Eastern cooperative oncology group (ECOG) performance status 0-1 and life expectancy of at least 3 months
- Adequate organ function Recovery from prior therapy-related toxicities to Grade <=1 (except alopecia; neuropathy and endocrinopathies <=Grade 2)
- Ability to swallow oral medication and comply with study procedures
- Stable dose (>=30 days) of bisphosphonates or denosumab, if applicable
Ki nem vehet részt
- Participants with Inflammatory breast cancer or leptomeningeal disease or brain metastases, with the exception of patients with definitively treated brain metastases that are clinically stable and asymptomatic for >2 weeks and who are off or receiving low-dose corticosteroid treatment (<=10 mg prednisone or equivalent) for at least 2 weeks prior to start of study treatment
- Ongoing corticosteroid use >10 mg/day (prednisone equivalent)
- Recent anticancer or investigational therapy within 14 days (28 days for fulvestrant)
- Major surgery within 28 days
- Recent major bleeding or uncontrolled bleeding disorder
- Significant cardiovascular disease within 6 months or ongoing uncontrolled cardiac conditions
- Active or uncontrolled infection (controlled HIV or treated hepatitis C allowed)
- Uncontrolled renal, pancreatic, or liver disease (excluding stable conditions such as Gilbert's syndrome or liver metastases)
- Another malignancy requiring treatment within 2 years (except low-risk, curatively treated cancers)
- Any condition that may interfere with safety or study compliance
- Untreated or unstable spinal cord compression
- Pregnancy or breastfeeding
Ez a vizsgálat jelenleg itt érhető el: Ausztrália.
Még 2 másik országban, 9 helyszínen
- Cancer Research SAAdelaide, AusztráliaRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to find out the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDEs) of JNJ-101684362 (HLD-0117), to evaluate the safety of JNJ-101684362 (HLD-0117) , and how well the participants can tolerate it in Part 1 (dose escalation) of the study.
A vizsgálat csoportja
- Arm 1A vizsgált kezelés
JNJ-101684362 (HLD-0117): Participants with estrogen receptor positive (ER+) metastatic breast cancer (MBC) will receive JNJ-101684362 (HLD-0117) orally once daily as monotherapy in Part 1 until recommended dose(s) for expansion has been developed. Participants in Part 2 will receive JNJ-101684362 (HLD-0117) at the RP2Ds developed in Part 1.
Kezelés: JNJ-101684362 (HLD-0117)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase 1 Study of JNJ-101684362 (HLD-0117) in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (MBC)
- A regiszteradat frissítve
- 2026. november 3.